Trends in Incidence and Epidemiology of Methicillin-Resistant Staphylococcus aureus Bacteremia, Six Emerging Infections Program Surveillance Sites, 2005–2022 - Scorecard - MDSpire
Advertisement
Trends in Incidence and Epidemiology of Methicillin-Resistant Staphylococcus aureus Bacteremia, Six Emerging Infections Program Surveillance Sites, 2005–2022
Clinical Scorecard: Shifts in the Incidence and Epidemiological Patterns of Methicillin-Resistant Staphylococcus aureus Bacteremia: Insights from Six Emerging Infections Program Surveillance Locations, 2005–2022
MRSA causes bloodstream infections with high mortality; epidemiology includes hospital-onset, health care–associated community-onset, and community-associated infections influenced by healthcare exposures and community transmission
Target Population
Residents of six US surveillance sites totaling approximately 12.6 million people
Care Setting
Hospital and community settings including healthcare facilities and general population
Key Highlights
MRSA bacteremia incidence declined from 2005 to 2016 but reversed with increases from 2016 to 2019.
During 2020–2022, hospital-onset MRSA bacteremia incidence increased, partly driven by patients with recent COVID-19 infection.
Community-associated and health care–associated community-onset MRSA bacteremia incidence decreased during the COVID-19 pandemic, potentially due to mitigation measures.
Guideline-Based Recommendations
Diagnosis
Identify MRSA bacteremia by isolation of MRSA from blood cultures in symptomatic patients.
Classify cases by epidemiologic categories: hospital-onset, health care–associated community-onset, and community-associated.
Management
Implement robust infection prevention and control measures, especially in hospital settings and among patients with recent COVID-19.
Continue surveillance to monitor MRSA bacteremia trends and guide interventions.
Monitoring & Follow-up
Use active laboratory- and population-based surveillance to track MRSA bacteremia incidence and epidemiological patterns.
Monitor the impact of COVID-19 and related healthcare disruptions on MRSA bacteremia rates.
Risks
Patients with recent COVID-19 infection have higher risk of hospital-onset MRSA bacteremia.
Healthcare system strain and disruptions during the COVID-19 pandemic may increase healthcare-associated MRSA infections.
Patient & Prescribing Data
Patients with MRSA bacteremia identified in six US surveillance sites from 2005 to 2022, including those with recent COVID-19 infection.
Increased hospital-onset MRSA bacteremia during COVID-19 pandemic highlights need for targeted infection prevention; no specific antimicrobial prescribing data provided.
Clinical Best Practices
Maintain and strengthen infection prevention protocols in healthcare settings, particularly during pandemics.
Screen and monitor patients with recent COVID-19 for MRSA bacteremia risk.
Utilize epidemiologic classification to tailor infection control strategies.
Leverage active surveillance data to identify trends and inform public health responses.
by Holly M Biggs, Rongxia Li, Kelly A Jackson, Joelle Nadle, Susan Petit, Susan M Ray, Ruth Lynfield, Kathryn Como-Sabetti, Ghinwa Dumyati, Anita Gellert, Marissa Walsh, William Schaffner, James Baggs, Isaac See
